Endometrial Cancer Market - Growth, Trends, and Forecasts (2023 - 2028)

Endometrial Cancer Market - Growth, Trends, and Forecasts (2023 - 2028)

The endometrial cancer market is expected to register a CAGR of 4.9% during the forecast period.

The COVID-19 pandemic had a moderate impact on the endometrial cancer market due to the reduction in patient visits for diagnosis during the initial phases of the COVID-19 pandemic. As per a study published in January 2022 in PubMed, the corona outbreak correlated with the disruption of screening activities and diagnostic assessments.

Endometrial cancer (EC) is one of the most common gynecological malignancies, and it is often detected at an early stage because it frequently produces symptoms. The data suggested that the COVID-19 pandemic had a significant impact on the characteristics and patterns of care of EC patients. However, post-pandemic, the market is anticipated to witness growth due to a rise in the incidence of endometrial cancer cases, an increase in healthcare expenditure, and technological advancements in endometrial cancer diagnosis and treatment.

For instance, as per a September 2022 update from Cancer Australia, an estimated 3,343 new cases of uterine cancer were diagnosed in Australia in 2022. Similarly, as per a Canadian Cancer Society May 2022 update, an estimated 8,100 Canadian women were likely to be diagnosed with uterine cancer in 2022. As per a May 2021 update from the Mayo Clinic, endometrial cancer begins in the layer of cells that form the lining (endometrium) of the uterus. Endometrial cancer is sometimes called uterine cancer.

Moreover, the rise in awareness programs and collaboration relating to endometrial cancer is anticipated to boost market growth. For instance, in March 2021, Eisai Inc. launched an initiative called ‘Spot Her’ to end the silence around endometrial cancer and inspire women to listen, advocate, and put their health and the health of other women first. The initiative was conducted in partnership with SHARE Cancer Support (SHARE), Facing Our Risk of Cancer Empowered (FORCE), and Black Health Matters. Moreover, in November 2021, the UNC Lineberger Comprehensive Cancer Center launched the Endometrial Cancer Center of Excellence to advance the scientific understanding of the causes, prevention, and clinical treatment of endometrial cancer and aid researchers in discovering the underlying factors that contribute to why black women in North Carolina are twice as likely to die from endometrial cancer. Such developments spread awareness about endometrial cancer, thereby boosting the demand for the endometrial cancer treatment market.

Factors, such as those mentioned above play a big role in boosting the market growth. But, the high cost associated with the treatment, the adverse effects of the treatment, and the high toxicity of drugs can be a hindrance.

The chemotherapy segment is expected to witness growth in the endometrial cancer market owing to the factors such as the increasing prevalence of endometrial cancer requiring chemotherapies and the rise in chemotherapy product developments. Chemotherapy is widely accepted for endometrial cancer since, after surgery, chemotherapy (chemo) with or without radiation therapy is given to help keep cancer from coming back. For instance, as per an article published in February 2022 in PubMed, combining the two drugs (Lenvatinib plus Pembrolizumab) led to longer progression-free survival and overall survival among patients than chemotherapy. Furthermore, per the statistics by the American Cancer Society updated in 2022, there were more than 600,000 endometrial cancer survivors in the United States. As per the same source, around 65,950 new cases of cancer of the body of the uterus (uterine body or corpus) were expected to be diagnosed in 2022. Thus, the demand for chemotherapy may rise with the growing burden of endometrial cancer.

According to the American Cancer Society, endometrial cancer is treated with chemotherapy drugs such doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil), cisplatin, and docetaxel (Taxotere). Furthermore, as per a study published in January 2022 in PubMed, front-line treatment for women with advanced endometrial cancer was firmly established as platinum-based chemotherapy plus taxane. Such studies indicate the efficacy of chemotherapy in the treatment of endometrial cancer. Furthermore, as per an article published in June 2022 by PubMed, over 90% of patients who got adjuvant chemotherapy for endometrial cancer and underwent hysterectomy also received platinum-taxane combination chemotherapy, and nearly 70% of patients who recurred initially were given platinum- or taxane-based therapy. Similarly as per an article published in October 2022 in MDPI, researchers found that the addition of trastuzumab to chemotherapy for high expressers of Her2/neu in endometrial serous carcinoma improved overall survival. Owing to such advantages offered by chemotherapy in endometrial cancer survival, the segment is likely to witness growth over the forecast period.

North America is expected to witness growth in the endometrial cancer market over the forecast period owing to factors such as the rising awareness of the diagnosis of cancer and the country's well-developed healthcare infrastructure. The American Cancer Society estimated about 65,950 new cases of cancer of the body of the uterus (uterine body or corpus) were likely to be diagnosed in the United States. Endometrial cancer affects mainly post-menopausal women. The average age of women diagnosed with endometrial cancer is 60.

Furthermore, there are many clinical studies of endometrial cancer conducted in the studied region. For instance, in July 2022, Canada-based Sunnybrook Health Sciences Centre sponsored a clinical study to assess the effect of megestrol acetate on grade 2 endometrioid endometrial cancer in patients waiting for definitive surgery. Moreover, several market players are engaged in the implementation of strategic initiatives across the region. For instance, in February 2022, Karyopharm Therapeutics Inc., based in the United States, reported positive top-line results from the Phase 3 Selinexor endometrial cancer study, evaluating the efficacy and safety of front-line maintenance therapy using selinexor in patients with advanced or recurrent endometrial cancer.

The endometrial cancer market is moderately competitive and consists of several major players. Due to the rising prevalence of cancer, there are several products under trial; henceforth, it is expected that a few other smaller players may enter the market. Some of the major players in the market are Bristol-Myers Squibb Company, Pfizer Inc., R-Pharm-US LLC, Elekta AB, and Siemens Healthineers (Varian Medical Systems, Inc.), among others.

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support